5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital

BACKGROUND: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents. Recent reports have raised concerns about their safety, especially with regard to neuropsychiatric adverse effects (neuropsychiatric AEs)....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur J Hosp Pharm
Главные авторы: Lopez, TLopez Viñau, de Molina, MD López Malo, de Vicente, M Sáez-Torres, Donoso, J López-Santamaria, Torres, IReyes, Parada, J Hernández
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Group 2018
Предметы:
Section 5: Patient safety and quality assurance
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535272/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.404
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы